Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intramuscular versus intravenous sotrovimab in high-risk non-hospitalized patients with mild/moderate COVID-19
2021-000623-13Phase 3Active
- Sponsor
- Vir Biotechnology
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sotrovimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Vir Biotechnology. Primary endpoint: Progression of COVID-19 through Day 29. Started Jun 2021; status: active.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000623-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000623-13.